Latest news
Sermo CEO Peter Kirk, after being diagnosed with acute myeloid leukemia and receiving a bone marrow transplant, went from running only 99 seconds initially to completing the New York Marathon, and founded the 'Run with Peter' global doctor running fundraiser. His story demonstrates the power of setting goals, making public commitments, and community support.
The career of Dr. José Trevejo, Chief Medical Officer of Tarsus Pharmaceuticals, began with his childhood experience of running to seek medical help for his mother who had malaria. Today, he is leading his team to advance TP-03 as the first FDA-approved treatment for Demodex blepharitis, a condition affecting approximately 25 million patients in the United States.
After COVID-19 monoclonal antibodies successively withdrew due to viral mutations, Invivyd is advancing early clinical trials of its next-generation antibody VYD222. CEO David Hering, who previously participated in the launch of Pfizer's vaccine, now targets the unmet needs of immunocompromised populations and attempts to address continuous viral mutations through engineered modifications.
Determined to enter the pharmaceutical industry at age 15, Chantal Friebertshäuser joined Moderna late last year after stints at Eli Lilly and Merck, overseeing commercial operations in Europe, the Middle East, Canada, and Australia. She firmly believes that viruses know no borders and that global health collaboration is the only way forward.
BeiGene is accelerating its international expansion. Christiane Langer, Senior Vice President of Global Medical Affairs, shares her career journey, the company's clinical data advantages, and strategies for addressing controversies over the quality of clinical trials in China.
Priyanka Dutta-Passecker, CEO and co-founder of Swiss biotech startup Healiva, deeply realized the importance of personal connections after visiting patients in India. She leverages her long-standing network spanning from the US to Europe to drive her company forward, emphasizing the critical role of connections in fundraising and innovation.
BioAge Labs co-founder and CEO Kristen Fortney is dedicated to extending human healthspan by targeting the molecular mechanisms of aging. The company uses an AI platform to analyze biobank data, developing therapies for aging-related diseases such as muscle atrophy, and has achieved positive clinical results.
During his time at Bayer, Rafiq Hasan was deeply moved by a patient who could see leaves clearly after an Eylea injection, which made him realize the power of narrative. Now as CEO of Complement Therapeutics, he leads a team developing therapies for complement system-mediated diseases, with lead drug CTx001 potentially offering a one-time gene therapy for geographic atrophy. The company has launched the i-GAIN natural history study to precisely screen patients and is nearing completion of its Series A financing. Hasan emphasizes that beyond science, simple and clear communication is equally important.
Biohaven CEO Vlad Coric never plays by the rules. After selling the migraine blockbuster drug Nurtec to Pfizer for $11.6 billion, he chose to return the company to a small, agile, clinically driven model, focusing on unmet areas such as obsessive-compulsive disorder and epilepsy. This article reveals his unique 'fast follower' strategy, unconventional business deal designs, and his steadfast belief in neuroscience drug development.
Rare disease patients and the Black community face similar inequalities in healthcare access, diagnostic delays, and quality of care. Alexion executive Tamar Thompson, drawing on personal experience, calls for policy reform and highlights the potential impact of the Inflation Reduction Act on rare disease research and development.